Despite evidence that adverse drug events manifest with greater severity in pediatric populations than in adults, fewer than 50% of drugs have been systematically studied for pediatric use. The lack of robust drug safety data may result in suboptimal or harmful treatment strategies. Saurabh Rahurkar and Pallavi Jonnalagadda share their team's efforts to address this issue. This podcast and article specifically address the use of benzonatate in pediatric patients. Read the full text open access manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.70061.